SEO URLwww.firestrike.ai/deals/35pharma-gsk-acquisition-2026-3
acquisitionAnnounced · Feb 25, 2026biopharmaceuticalSource · CredibleArticle · Factual
GSK acquires 35Pharma
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$950M
Target
35Pharma
Acquirer
GSK
Full Acquisition
Status
Announced
GSK agreed to acquire 35Pharma. Reported deal value: $950M. Status: Announced. Sector: biopharmaceutical. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-02-25. Figures and status may change as filings and press coverage update.
35Pharma , a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announced it has entered into an agreement with GSK plc , under which GSK will acquire all of the outstanding equity interests in 35Pharma
Deal timeline
Announced
Feb 25, 2026 · globenewswire.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biopharmaceutical with a reported deal value of $950M. Figures and status may change as sources update.
Sources: globenewswire.com · Primary article · FireStrike proprietary index